Back to top

Image: Bigstock

Immune Design Corp.

Read MoreHide Full Article

Immune Design’s primary candidates, CMB305 is being evaluated for soft tissue sarcoma and G100 for Merkel cell carcinoma , follicular non-Hodgkin Lymphoma and sarcoma. The company expects to provide data this year on both the lead product candidate from both monotherapy and combination studies to support their potential registration paths towards commercialization. We are positive on its strategic agreements with companies like Sanofi, Roche, and Merck, which not only validate its GLAAS platform, but also provide the company with funds in the form of collaboration and license revenues. The company’s shares have outperformed the Medical-Drugs industry year to date. However, the company is highly dependent on its collaboration partners for funds which increases its vulnerability.

Published in